PTK6 and breast cancer: Importantly, the antiproliferative potency of eCF506 in the sensitive breast cancer cells correlated well with the observed inhibition of SRC-pY419, although the potential contribution of partly inhibiting other targets (e.g., BRK) cannot be ruled out.